Abstract
Purpose
Gastroenterologists have been seeking reliable noninvasive indices of inflammatory and malignant bowel disease. This prospective study was to assess the value of fecal calprotectin in predicting abnormal histologic findings in patients undergoing colonoscopy.
Methods
Stool specimens supplied before colonoscopy by 72 consecutive patients were measured for calprotectin levels, and the findings correlated with the colonoscopy results and other fecal and blood parameters. Receiver operating characteristics curve analysis was used to determine the predictive value of fecal calprotectin for abnormal colonic histology.
Results
Patients with abnormal histologic findings had significantly higher calprotectin levels (218 ± 125 mg percent) than patients with normal colonoscopy (77 ± 100 mg percent). There was a highly significant correlation between calprotectin levels and erythrocyte sedimentation rate (r = 0.45, P = 0.008), positive fecal occult blood test (r = 0.57, P = 0.0001), and abnormal colonic histology (r = 0.54, P = 0.0001). Patients with active inflammatory bowel disease had higher calprotectin levels than the rest of the study patients (r = 0.3; P = 0.01). On multivariate analysis, calprotectin was a significant predictor of abnormal colonic histology (P = 0.005; odds ratio, 1.007; 95 percent confidence interval, 1.002–1.012). The area under the receiver operating characteristics curve was 0.79. A fecal calprotectin concentration of 150 μg/ml had a sensitivity of 75 percent, specificity of 84 percent, positive predictive value of 80 percent, and negative predictive value of 75 percent in predicting abnormal colonic histology.
Conclusions
Fecal calprotectin may serve as a simple, noninvasive surrogate marker of abnormal histologic findings in patients scheduled for colonoscopy.
Similar content being viewed by others
References
Hoff G, Grotmol T, Thilis-Evensen E, et al. Testing for fecal calprotectin in the Norwegian colorectal cancer prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood. Gut 2004;53:1329–33.
Ton H, Brandness Q, Holtlund J, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.
Kronborg O, Ustad M, Fuglerud P, et al. Fecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000;46:795–800.
Limburg PJ, Devens ME, Harrington JJ, et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003;98:2299–305.
Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15–22.
Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as a non-invasive marker of intestinal inflammation. Dig Liver Dis 2003;35:642–7.
Fagerhol MK. Calprotectin. A faecal marker of organic gastrointestinal abnormality. Lancet 2000;356:1783–4.
Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174–8.
Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroenterol 1994;89:53–65.
Kristinsson J, Roseth A, Fagerhol MK, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998;41:316–21.
Gilbert JA, Ahlquist DA, Mahoney DW, et al. Fecal marker variability in colorectal cancer: calprotectin versus hemoglobin. Scand J Gastroenterol 1996;31:1001–5.
Dale IB, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L-1) in human peripheral blood leukocytes. Am J Clin Pathol 1985;84:24–34.
Fagerhol MK, Dale I, Anderson I. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol 1980;24:393–8.
Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073–6.
Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001;49:402–8.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Shitrit, A.BG., Braverman, D., Stankiewics, H. et al. Fecal Calprotectin as a Predictor of Abnormal Colonic Histology. Dis Colon Rectum 50, 2188–2193 (2007). https://doi.org/10.1007/s10350-007-9038-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10350-007-9038-x